Late-Breaking Science preview: Wednesday, Nov. 15 The ultimate Late-Breaking Science session delves into innovative therapies and novel applications, including two phase 1-2 stem cell trials, an early on trial in toxin treatments to avoid atrial fibrillation, a phase 1 test of the interatrial shunt device for heart failure with preserved ejection fraction, and more: TNT-POAF: Nathan Waldron, MD, of Duke University or college, Durham, N.C., will show results of the trial looking to prevent postoperative atrial fibrillation by using short-term toxin treatment.REDUCE LAP-HF 1: In what the researchers contact the first randomized controlled trial of the device-based therapy to lessen remaining atrial pressure in HFpEF, an inter-atrial shunt gadget made to provide active and continuous decompression from the remaining atrium.The disruptors issue has pitted agriculture and industry against consumer and environmental groups for quite some time. The EU even announced this past year it had reached broad agreement on what chemicals were involved but had to return towards the sketching board amid controversy. Tuesday’s decision was created by a Percentage technical group but all 28 member expresses must formally endorse next three months to consider it forward. The Fee statement gave no information on the criteria agreed.
No increased risks to newborns linked to taking influenza drugs during pregnancy A report published with the BMJ today sees no increased dangers to newborn infants if their moms have taken medicines to avoid or deal with influenza during being pregnant. This is actually the largest study up to now to assess potential risks of taking antiviral drugs during pregnancy as well as the results support previous findings.